https://minerva.lifescicreative.com/press_releases/minerva-neurosciences-announces-pricing-of-initial-public-offering/ 2014-06-30T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/minerva-neurosciences-to-ring-nasdaq-stock-market-closing-bell-on-july-7-2014/ 2014-07-07T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/minerva-neurosciences-announces-appointment-of-frederick-w-ahlholm-as-vp-of-finance-and-chief-accounting-officer/ 2014-07-14T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/minerva-neurosciences-to-host-second-quarter-2014-financial-results-webcast-and-conference-call/ 2014-07-31T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/minerva-neurosciences-reports-second-quarter-2014-financial-results/ 2014-08-07T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/mark-s-levine-joins-minerva-neurosciences-as-vp-and-general-counsel/ 2014-08-18T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/minerva-neurosciences-to-present-at-baird-2014-health-care-conference/ 2014-08-28T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/minerva-neurosciences-announces-completion-of-fda-review-of-investigational-new-drug-application-for-min-202-and-plans-for-first-u-s-based-clinical-trial/ 2014-09-22T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/minerva-neurosciences-to-host-third-quarter-2014-financial-results-webcast-and-conference-call/ 2014-10-30T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/minerva-neurosciences-reports-third-quarter-2014-financial-results/ 2014-11-06T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/dr-remy-luthringer-minerva-president-and-chief-scientific-officer-to-present-at-cns-summit/ 2014-11-13T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/minerva-neurosciences-appoints-dr-remy-luthringer-as-ceo/ 2014-11-25T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/minerva-neurosciences-announces-completion-of-development-and-final-selection-of-once-daily-dose-formulation-of-min-101-for-its-schizophrenia-program/ 2014-12-03T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/minerva-neurosciences-reports-positive-data-showing-an-analog-of-minervas-min-301-compound-improves-symptoms-of-parkinsons-disease-in-primates/ 2015-01-05T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/minerva-neurosciences-announces-15-million-debt-facility-with-oxford-finance-llc-and-silicon-valley-bank/ 2015-01-20T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/minerva-neurosciences-reports-positive-phase-1-data-with-min-202-selective-orexin-2-antagonist-for-treatment-of-sleep-disorders-including-primary-and-comorbid-insomnia/ 2015-01-21T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/minerva-neurosciences-announces-31-million-financing/ 2015-03-13T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/minerva-neurosciences-completes-private-placement-raises-31-million/ 2015-03-18T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/minerva-neurosciences-to-host-fourth-quarter-and-full-year-2014-financial-results-webcast-and-conference-call/ 2015-03-19T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/minerva-neurosciences-reports-fourth-quarter-and-full-year-2014-financial-results/ 2015-03-26T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/minerva-neurosciences-to-host-first-quarter-2015-financial-results-webcast-and-conference-call/ 2015-04-30T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/minerva-neurosciences-reports-first-quarter-2015-financial-results-and-other-key-business-updates/ 2015-05-07T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/minerva-neurosciences-announces-appointment-of-dr-fouzia-laghrissi-thode-to-its-board-of-directors/ 2015-05-18T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/minerva-neurosciences-to-present-at-upcoming-investor-conferences-in-june/ 2015-05-28T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/minerva-neurosciences-provides-update-on-min-202-selective-orexin-2-receptor-antagonist/ 2015-06-16T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/minerva-neurosciences-to-report-second-quarter-2015-financial-results-and-host-conference-call-on-august-5-2015/ 2015-07-29T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/minerva-neurosciences-reports-second-quarter-2015-financial-results-and-business-updates/ 2015-08-05T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/minerva-neurosciences-to-present-at-baird-2015-healthcare-conference-on-september-9-2015/ 2015-09-02T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/minerva-neurosciences-provides-update-on-clinical-development-program-with-min-202-selective-orexin-2-receptor-antagonist/ 2015-09-24T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/minerva-neurosciences-to-report-third-quarter-2015-financial-results-and-host-conference-call-on-november-5-2015/ 2015-10-29T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/minerva-neurosciences-announces-appointment-of-dr-david-kupfer-to-its-board-of-directors/ 2015-11-02T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/minerva-neurosciences-reports-third-quarter-2015-financial-results-and-business-updates/ 2015-11-05T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/minerva-neurosciences-to-present-at-jefferies-2015-london-healthcare-conference-on-november-18-2015/ 2015-11-13T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/minerva-provides-year-end-update-on-clinical-trials-with-three-central-nervous-system-product-candidates/ 2015-12-09T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/minerva-achieves-enrollment-target-in-phase-iib-trial-with-min-101/ 2015-12-18T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/minerva-neurosciences-announces-update-on-min-101-clinical-development-program/ 2015-12-29T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/minerva-neurosciences-announces-favorable-top-line-results-from-min-202-phase-2a-clinical-trial-in-insomnia-disorder/ 2016-01-11T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/minerva-neurosciences-announces-top-line-data-from-min-202-phase-i-clinical-study-in-japanese-patients/ 2016-02-01T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/minerva-neurosciences-announces-completion-of-patient-enrollment-in-phase-iia-trial-of-min-117-in-major-depressive-disorder/ 2016-02-22T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/minerva-neurosciences-to-report-fiscal-2015-fourth-quarter-and-year-end-financial-results-and-business-updates-on-march-14-2016/ 2016-03-07T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/minerva-neurosciences-announces-positive-top-line-results-from-phase-ib-clinical-trial-in-major-depressive-disorder-with-min-202/ 2016-03-11T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/minerva-neurosciences-reports-fiscal-2015-fourth-quarter-and-year-end-financial-results-and-business-updates/ 2016-03-14T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/minerva-neurosciences-to-report-first-quarter-2016-financial-results-and-business-updates-on-may-3-2016/ 2016-04-26T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/minerva-neurosciences-reports-first-quarter-2016-financial-results-and-business-updates/ 2016-05-03T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/minerva-neurosciences-announces-positive-results-in-phase-iia-trial-of-min-117-in-major-depressive-disorder/ 2016-05-26T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/minerva-neurosciences-announces-positive-results-from-phase-iib-trial-of-min-101-monotherapy-in-schizophrenia/ 2016-05-26T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/minerva-neurosciences-to-present-at-jefferies-2016-healthcare-conference-on-june-8-2016/ 2016-06-01T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/minerva-neurosciences-announces-proposed-public-offering-of-common-stock/ 2016-06-13T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/minerva-neurosciences-to-present-at-jmp-securities-life-sciences-conference-june-21-2016/ 2016-06-14T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/minerva-neurosciences-announces-pricing-of-public-offering-of-common-stock-2/ 2016-06-14T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/minerva-neurosciences-set-to-join-russell-3000-and-russell-2000-indexes/ 2016-06-27T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/minerva-neurosciences-to-report-second-quarter-2016-financial-results-and-business-updates-on-august-4-2016/ 2016-07-28T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/minerva-neurosciences-reports-second-quarter-2016-financial-results-and-business-updates/ 2016-08-04T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/minerva-neurosciences-to-present-at-23rd-annual-newsmakers-in-the-biotech-industry-conference-on-september-9-2016/ 2016-09-02T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/minerva-neurosciences-provides-update-on-min-101-and-min-117-clinical-programs/ 2016-09-26T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/minerva-neurosciences-announces-acceptance-of-presentations-of-clinical-data-with-min-101-and-min-117-at-american-college-of-neuropsychopharmacology-annual-meeting/ 2016-10-13T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/minerva-neurosciences-announces-positive-data-from-six-month-extension-of-phase-iib-trial-of-min-101-monotherapy-in-schizophrenia/ 2016-10-26T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/minerva-neurosciences-to-report-third-quarter-2016-financial-results-and-business-updates-on-november-3-2016/ 2016-10-27T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/minerva-neurosciences-reports-third-quarter-2016-financial-results-and-business-updates/ 2016-11-03T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/minerva-neurosciences-to-present-at-jefferies-2016-london-healthcare-conference-on-november-17-2016/ 2016-11-10T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/minerva-neurosciences-clinical-data-featured-at-the-american-college-of-neuropsychopharmacology-annual-meeting/ 2016-12-05T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/minerva-neurosciences-names-michael-davidson-m-d-as-chief-medical-officer/ 2016-12-20T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/additional-data-analyses-from-phase-iib-trial-of-min-101-in-schizophrenia-underscore-benefit-in-multiple-measurements-of-cognitive-function/ 2017-01-20T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/minerva-neurosciences-to-host-rd-day-focused-on-unmet-needs-and-emerging-treatment-strategies-in-schizophrenia/ 2017-02-21T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/minerva-neurosciences-to-present-at-cowen-and-company-37th-annual-health-care-conference-on-march-7-2017/ 2017-02-28T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/minerva-neurosciences-to-report-fiscal-2016-fourth-quarter-and-year-end-financial-results-and-business-updates-on-march-13-2017/ 2017-03-06T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/minerva-neurosciences-reports-fiscal-2016-fourth-quarter-and-year-end-financial-results-and-business-updates/ 2017-03-13T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/minerva-neurosciences-announces-recent-exercise-of-warrants-by-institutional-stockholders-and-open-market-purchase-of-common-stock-by-chairman-of-its-board-of-directors/ 2017-03-21T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/minerva-neurosciences-to-report-first-quarter-2017-financial-results-and-business-updates-on-may-4-2017/ 2017-04-27T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/minerva-neurosciences-reports-first-quarter-2017-financial-results-and-business-updates/ 2017-05-04T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/minerva-provides-update-on-phase-3-design-and-development-strategy-for-min-101/ 2017-05-15T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/minerva-announces-outcome-of-end-of-phase-2-meeting-with-fda/ 2017-05-15T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/minerva-neurosciences-to-present-at-jefferies-2017-healthcare-conference-on-june-6-2017/ 2017-05-30T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/minerva-announces-amended-agreement-for-min-202-in-insomnia/ 2017-05-31T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/minerva-announces-completion-of-bridging-study-to-select-improved-formulation-of-min-101-for-use-in-phase-3-trial-for-the-treatment-of-negative-symptoms-in-patients-with-schizophrenia/ 2017-06-22T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/minerva-neurosciences-inc-to-offer-common-shares/ 2017-06-27T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/minerva-neurosciences-announces-pricing-of-public-offering-of-common-stock/ 2017-06-28T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/minerva-neurosciences-announces-closing-of-public-offering-of-common-stock-and-full-exercise-of-underwriters-option-to-purchase-additional-shares/ 2017-07-05T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/minerva-neurosciences-announces-departure-of-directors/ 2017-07-24T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/minerva-neurosciences-to-report-second-quarter-2017-financial-results-and-business-updates-on-august-3-2017/ 2017-07-27T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/american-journal-of-psychiatry-publishes-minerva-neurosciences-min-101-phase-2b-trial-results-for-treatment-of-negative-symptoms-in-schizophrenia/ 2017-07-31T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/minerva-neurosciences-reports-second-quarter-2017-financial-results-and-business-updates/ 2017-08-03T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/minerva-neurosciences-announces-european-commission-approval-of-amendment-of-min-202-agreement-with-janssen/ 2017-08-25T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/minerva-neurosciences-announces-enrollment-of-first-patient-in-phase-2b-trial-of-seltorexant-min-202-as-adjunctive-therapy-in-patients-with-major-depressive-disorder/ 2017-09-05T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/minerva-neurosciences-names-dr-jay-saoud-as-senior-vice-president-head-of-research-and-development/ 2017-09-11T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/minerva-neurosciences-to-report-third-quarter-2017-financial-results-and-business-updates-on-november-6-2017/ 2017-10-30T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/minerva-neurosciences-names-dr-justine-lalonde-as-senior-vice-president-product-strategy/ 2017-10-31T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/minerva-neurosciences-reports-third-quarter-2017-financial-results-and-business-updates/ 2017-11-06T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/minerva-neurosciences-to-present-at-jefferies-2017-london-healthcare-conference-on-november-15-2017/ 2017-11-08T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/minerva-neurosciences-announces-enrollment-of-first-patient-in-phase-2b-trial-of-seltorexant-min-202-in-patients-with-insomnia-disorder/ 2017-12-06T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/minerva-neurosciences-names-richard-russell-president/ 2017-12-11T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/minerva-neurosciences-elects-william-doyle-and-hans-peter-hasler-to-board-of-directors/ 2017-12-11T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/minerva-neurosciences-screens-first-patient-in-phase-3-trial-of-min-101-to-treat-negative-symptoms-in-schizophrenia/ 2017-12-19T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/minerva-neurosciences-announces-enrollment-of-first-patient-in-phase-2b-trial-comparing-seltorexant-min-202-versus-quetiapine-as-adjunctive-therapy-to-antidepressants-in-patients-with-majo/ 2017-12-21T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/minerva-neurosciences-names-remy-luthringer-as-executive-chairman-and-william-doyle-as-lead-independent-director/ 2018-02-05T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/minerva-neurosciences-to-report-fiscal-2017-fourth-quarter-and-year-end-financial-results-and-business-updates-on-march-12-2018/ 2018-03-05T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/minerva-neurosciences-reports-fiscal-2017-fourth-quarter-and-year-end-financial-results-and-business-updates/ 2018-03-12T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/minerva-neurosciences-to-host-key-opinion-leader-meeting-on-the-negative-symptoms-of-schizophrenia-on-thursday-march-22/ 2018-03-15T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/minerva-neurosciences-screens-first-patient-in-phase-2b-trial-of-min-117-to-treat-major-depressive-disorder/ 2018-04-09T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/minerva-neurosciences-to-report-first-quarter-2018-financial-results-and-business-updates-on-may-3-2018/ 2018-04-26T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/minerva-neurosciences-reports-first-quarter-2018-financial-results-and-business-updates/ 2018-05-03T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/journal-of-clinical-psychiatry-publishes-positive-results-of-cognitive-performance-from-phase-2b-trial-of-roluperidone-under-development-by-minerva-neurosciences-for-the-treatment-of-negative-symptom/ 2018-05-17T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/minerva-neurosciences-to-present-at-jefferies-2018-global-healthcare-conference-on-june-6-2018/ 2018-05-30T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/minerva-neurosciences-elects-jeryl-hilleman-to-board-of-directors/ 2018-07-17T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/minerva-neurosciences-names-devin-smith-senior-vice-president-general-counsel/ 2018-07-25T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/minerva-neurosciences-to-report-second-quarter-2018-financial-results-and-business-updates-on-august-2-2018/ 2018-07-26T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/minerva-neurosciences-reports-second-quarter-2018-financial-results-and-business-updates/ 2018-08-02T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/minerva-neurosciences-announces-findings-showing-effect-of-roluperidone-on-brain-derived-neurotrophic-factor-bdnf/ 2018-08-22T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/minerva-neurosciences-to-report-third-quarter-2018-financial-results-and-business-updates-on-november-5-2018/ 2018-10-29T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/minerva-neurosciences-reports-third-quarter-2018-financial-results-and-business-updates/ 2018-11-05T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/minerva-neurosciences-to-present-at-jefferies-london-healthcare-conference-on-november-14-2018/ 2018-11-07T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/minerva-neurosciences-to-host-roluperidone-update-and-key-opinion-leader-discussion-of-negative-symptoms-in-cns-psychiatric-diseases-on-november-20-2018/ 2018-11-15T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/minerva-neurosciences-announces-results-of-dose-escalation-study-evaluating-roluperidone-min-101-administered-at-supra-therapeutic-doses-in-healthy-volunteers/ 2018-11-19T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/minerva-neurosciences-to-present-at-evercore-isi-healthconx-conference-on-november-28-2018/ 2018-11-21T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/minerva-neurosciences-announces-new-patent-application-for-min-117-related-to-broad-effect-on-pain/ 2018-11-28T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/minerva-neurosciences-to-report-fiscal-2018-fourth-quarter-and-year-end-financial-results-and-business-updates-on-march-12-2019/ 2019-03-05T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/minerva-neurosciences-reports-fiscal-2018-fourth-quarter-and-year-end-financial-results-and-business-updates/ 2019-03-12T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/minerva-neurosciences-to-host-webcast-event-on-schizophrenia/ 2019-03-18T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/minerva-neurosciences-presents-pre-clinical-data-suggesting-a-mechanistic-role-of-roluperidone-in-addressing-negative-symptoms-of-schizophrenia/ 2019-04-11T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/minerva-neurosciences-to-report-first-quarter-2019-financial-results-and-business-updates-on-may-6-2019/ 2019-04-29T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/minerva-neurosciences-reports-first-quarter-2019-financial-results-and-business-updates/ 2019-05-06T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/minerva-neurosciences-announces-positive-top-line-results-in-phase-2b-clinical-trial-with-seltorexant-min-202-in-treatment-of-depressed-patients-with-an-inadequate-response-to-ssris-and-snris/ 2019-05-13T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/minerva-neurosciences-to-present-at-jefferies-2019-global-healthcare-conference-on-june-4-2019/ 2019-05-29T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/minerva-neurosciences-to-present-at-jmp-securities-life-sciences-conference-2/ 2019-06-12T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/minerva-neurosciences-to-host-live-conference-call-and-webcast-with-key-opinion-leaders-to-discuss-successful-insomnia-trial-with-seltorexant/ 2019-06-23T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/minerva-neurosciences-announces-achievement-of-primary-and-key-secondary-objectives-in-phase-2b-clinical-trial-of-seltorexant-min-202-in-insomnia/ 2019-06-24T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/minerva-neurosciences-to-report-second-quarter-2019-financial-results-and-business-updates-on-august-5-2019/ 2019-07-29T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/minerva-neurosciences-reports-second-quarter-2019-financial-results-and-business-updates/ 2019-08-05T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/catalent-and-minerva-neurosciences-enter-commercial-supply-agreement-for-schizophrenia-drug-roluperidone/ 2019-09-24T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/minerva-neurosciences-to-host-conference-call-and-live-webcast-on-tuesday-october-1-at-830-am-et/ 2019-09-26T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/minerva-neurosciences-announces-update-for-three-clinical-trials/ 2019-10-01T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/minerva-neurosciences-to-report-third-quarter-2019-financial-results-and-business-updates-on-november-4-2019/ 2019-10-28T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/minerva-neurosciences-reports-third-quarter-2019-financial-results-and-business-updates/ 2019-11-04T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/minerva-neurosciences-to-present-at-jefferies-london-healthcare-conference-on-november-21-2019/ 2019-11-14T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/minerva-neurosciences-reports-topline-results-from-phase-2b-trial-of-min-117-in-major-depressive-disorder/ 2019-12-18T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/minerva-neurosciences-announces-completion-of-patient-screening-in-phase-3-trial-of-roluperidone-for-the-treatment-of-negative-symptoms-in-schizophrenia/ 2020-01-06T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/minerva-neurosciences-announces-completion-of-patient-enrollment-in-phase-3-trial-of-roluperidone-for-the-treatment-of-negative-symptoms-in-schizophrenia/ 2020-02-05T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/minerva-neurosciences-to-host-key-opinion-leader-meeting-on-avolition-the-most-central-domain-for-the-successful-treatment-of-negative-symptoms-in-schizophrenia/ 2020-02-28T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/minerva-neurosciences-to-report-fiscal-2019-fourth-quarter-and-year-end-financial-results-and-business-updates-on-march-9-2020/ 2020-03-02T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/minerva-neurosciences-reports-fiscal-2019-fourth-quarter-and-year-end-financial-results-and-business-updates/ 2020-03-09T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/minerva-neurosciences-updates-market-on-share-price-drop-and-trading-halt/ 2020-03-12T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/minerva-neurosciences-to-host-key-opinion-leader-meeting-on-roluperidone-a-potentially-novel-mechanism-to-treat-the-negative-symptoms-of-schizophrenia/ 2020-03-24T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/minerva-neurosciences-to-report-first-quarter-2020-financial-results-and-business-updates-on-may-4-2020/ 2020-04-27T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/minerva-neurosciences-reports-first-quarter-2020-financial-results-and-business-updates/ 2020-05-04T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/minerva-neurosciences-announces-results-from-phase-3-trial-of-roluperidone-min-101-for-treatment-of-negative-symptoms-in-schizophrenia/ 2020-05-29T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/revised-webcast-call-information-minerva-neurosciences-to-hold-webcast-and-call-with-key-opinion-leaders-to-present-additional-analyses-from-phase-3-trial-of-roluperidone-min-101-for-treatment-of/ 2020-06-01T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/minerva-neurosciences-exercises-right-to-opt-out-of-agreement-with-janssen-for-seltorexant-min-202/ 2020-07-01T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/minerva-neurosciences-to-report-second-quarter-2020-financial-results-and-business-updates-on-august-3-2020/ 2020-07-27T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/minerva-neurosciences-reports-second-quarter-2020-financial-results-and-business-updates/ 2020-08-03T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/minerva-neurosciences-to-present-at-jmp-securities-cns-forum/ 2020-08-13T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/minerva-neurosciences-to-present-at-citis-15th-annual-biopharma-virtual-conference/ 2020-09-02T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/minerva-neurosciences-to-present-at-h-c-wainwright-22nd-annual-global-investment-conference/ 2020-09-09T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/minerva-neurosciences-to-report-third-quarter-2020-financial-results-and-business-updates-on-november-2-2020/ 2020-10-26T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/minerva-neurosciences-reports-third-quarter-2020-financial-results-and-business-updates/ 2020-11-02T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/minerva-neurosciences-to-present-at-jefferies-virtual-london-healthcare-conference/ 2020-11-09T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/minerva-neurosciences-announces-outcome-of-type-c-meeting-with-fda-and-next-steps-in-the-development-of-roluperidone/ 2020-12-01T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/minerva-neurosciences-and-royalty-pharma-announce-sale-of-seltorexant-royalty-for-up-to-155-million/ 2021-01-19T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/minerva-neurosciences-to-report-fiscal-2020-fourth-quarter-and-year-end-financial-results-and-business-updates-on-march-8-2021/ 2021-03-01T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/minerva-neurosciences-reports-fiscal-2020-fourth-quarter-and-year-end-financial-results-and-business-updates/ 2021-03-08T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/minerva-neurosciences-to-report-first-quarter-2021-financial-results-and-business-updates-on-may-12-2021/ 2021-05-05T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/minerva-neurosciences-announces-the-results-of-the-phase-3-trial-of-roluperidone-for-the-treatment-of-negative-symptoms-of-schizophrenia-following-the-completion-of-the-40-week-open-label-extension/ 2021-05-11T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/minerva-neurosciences-reports-first-quarter-2021-financial-results-and-business-updates/ 2021-05-12T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/minerva-neurosciences-to-present-at-jefferies-virtual-healthcare-conference/ 2021-05-28T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/minerva-neurosciences-to-present-at-jmp-securities-life-sciences-conference/ 2021-06-10T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/minerva-neurosciences-to-report-second-quarter-2021-financial-results-and-business-updates-on-august-2-2021/ 2021-07-26T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/minerva-neurosciences-reports-second-quarter-2021-financial-results-and-business-updates/ 2021-08-02T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/minerva-neurosciences-announces-appointment-of-dr-ramana-kuchibhatla-as-senior-vice-president-and-head-of-research-development/ 2021-09-08T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/minerva-neurosciences-announces-study-results-demonstrating-bioequivalence-of-phase-2b-phase-3-and-planned-commercial-formulations-of-roluperidone-for-treatment-of-negative-symptoms-of-schizophrenia/ 2021-09-30T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/minerva-neurosciences-announces-promotion-of-geoff-race-to-president/ 2021-10-11T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/minerva-neurosciences-to-report-third-quarter-2021-financial-results-and-business-updates-on-november-8/ 2021-11-01T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/minerva-neurosciences-announces-fda-recommendation-for-type-c-meeting-to-discuss-evidence-for-use-of-roluperidone-as-monotherapy-for-the-treatment-of-negative-symptoms-in-patients-with-schizophrenia-i/ 2021-11-03T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/minerva-neurosciences-reports-third-quarter-2021-financial-results-and-business-updates/ 2021-11-08T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/minerva-neurosciences-announces-publication-of-roluperidone-phase-3-study-results-in-schizophrenia-bulletin/ 2022-02-28T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/minerva-neurosciences-reports-fourth-quarter-2021-financial-results-and-business-updates/ 2022-03-01T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/minerva-neurosciences-provides-update-from-type-c-meeting-with-fda-and-next-steps-in-preparation-for-submission-of-a-new-drug-application-nda-for-roluperidone-for-the-treatment-of-negative-symptoms/ 2022-04-07T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/minerva-neurosciences-reports-first-quarter-2022-financial-results-and-business-updates/ 2022-05-04T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/minerva-neurosciences-reports-second-quarter-2022-financial-results-and-business-updates/ 2022-08-09T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/minerva-neurosciences-submits-new-drug-application-to-fda-for-roluperidone-for-the-treatment-of-negative-symptoms-in-patients-with-schizophrenia/ 2022-08-22T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/minerva-neurosciences-announces-listing-transfer-to-nasdaq-capital-market/ 2022-09-09T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/minerva-neurosciences-receives-refusal-to-file-letter-from-fda-for-its-new-drug-application-for-roluperidone-for-the-treatment-of-negative-symptoms-in-schizophrenia/ 2022-10-17T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/minerva-neurosciences-to-report-third-quarter-2022-financial-results-and-business-updates-on-november-9-2022/ 2022-11-02T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/minerva-neurosciences-reports-third-quarter-2022-financial-results-and-business-updates/ 2022-11-09T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/minerva-neurosciences-announces-update-on-its-new-drug-application-nda-for-roluperidone-for-the-treatment-of-negative-symptoms-in-schizophrenia-2/ 2022-12-28T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/minerva-neurosciences-to-report-fiscal-year-2022-financial-results-and-business-updates-on-march-8-2023/ 2023-03-01T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/minerva-neurosciences-reports-fiscal-year-2022-fourth-quarter-and-year-end-financial-results-and-business-updates/ 2023-03-08T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/minerva-neurosciences-announces-the-nda-filing-for-roluperidone-for-the-treatment-of-negative-symptoms-in-schizophrenia/ 2023-05-01T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/minerva-neurosciences-to-report-first-quarter-2023-financial-results-and-business-updates-on-may-15-2023/ 2023-05-08T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/minerva-neurosciences-announces-update-on-its-new-drug-application-nda-for-roluperidone-for-the-treatment-of-negative-symptoms-in-schizophrenia/ 2023-05-10T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/minerva-neurosciences-reports-2023-first-quarter-financial-results-and-business-updates/ 2023-05-15T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/minerva-neurosciences-announces-20-million-in-private-placement-priced-at-a-premium-to-market/ 2023-06-28T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/minerva-neurosciences-reports-2023-second-quarter-financial-results-and-business-updates/ 2023-08-01T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/minerva-neurosciences-reports-2023-third-quarter-financial-results-and-business-updates/ 2023-11-07T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/minerva-neurosciences-reports-fourth-quarter-and-fiscal-year-2023-financial-results-and-business-updates/ 2024-02-22T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/minerva-neurosciences-receives-complete-response-letter-from-fda-for-new-drug-application-for-roluperidone-for-the-treatment-of-negative-symptoms-in-patients-with-schizophrenia/ 2024-02-27T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/minerva-neurosciences-reports-first-quarter-2024-financial-results-and-business-updates/ 2024-05-01T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/minerva-neurosciences-reports-second-quarter-2024-financial-results-and-business-updates/ 2024-08-06T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/minerva-neurosciences-reports-third-quarter-2024-financial-results-and-business-updates/ 2024-11-05T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/minerva-neurosciences-reports-fourth-quarter-and-fiscal-year-2024-financial-results-and-business-updates/ 2025-02-25T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/minerva-neurosciences-reports-first-quarter-2025-financial-results-and-business-updates/ 2025-05-13T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/minerva-neurosciences-provides-business-updates-and-second-quarter-financial-results/ 2025-08-14T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/minerva-neurosciences-announces-financing-of-up-to-200-million-to-advance-roluperidone-for-the-treatment-of-negative-symptoms-in-patients-with-schizophrenia-through-a-phase-3-confirmatory-trial-and-r/ 2025-10-21T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/minerva-neurosciences-reports-third-quarter-2025-financial-results-and-business-updates/ 2025-11-05T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/minerva-neurosciences-appoints-dr-inderjit-kaul-to-the-companys-board-of-directors/ 2025-11-19T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/minerva-neurosciences-to-host-virtual-kol-event-to-discuss-roluperidone-from-unmet-need-to-reality-potentially-the-first-treatment-for-patients-with-negative-symptoms-of-schizophrenia-on-f/ 2026-01-26T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/minerva-neurosciences-to-participate-in-the-citizens-life-sciences-conference/ 2026-03-04T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/minerva-neurosciences-reports-fourth-quarter-and-fiscal-year-2025-financial-results-and-business-updates/ 2026-03-11T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/minerva-neurosciences-to-participate-in-the-stifel-2026-virtual-cns-forum/ 2026-03-12T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/minerva-neurosciences-presents-data-from-its-open-label-safety-trial-evaluating-roluperidone-co-administered-with-olanzapine-at-sirs-2026/ 2026-03-25T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/minerva-neurosciences-announces-first-patient-screened-in-global-phase-3-confirmatory-trial-of-roluperidone-for-the-treatment-of-negative-symptoms-of-schizophrenia/ 2026-03-31T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/minerva-announces-leadership-transition/ 2026-04-02T00:00:00+00:00 https://minerva.lifescicreative.com/press_releases/minerva-neurosciences-provides-first-quarter-2026-financial-results-and-business-updates/ 2026-05-05T00:00:00+00:00